Tharimmune, Inc. (THAR) - Dilution Analysis

10-Q filing | 69.8M shares outstanding

10-K filing | 56.7M shares outstanding

8-K filing: Tharimmune, Inc. entered into an underwriting agreement with Clear Street LLC for an offering of 1,800,000 shares of common stock at $2.92 per share and pre-funded warrants to purchase up to 17,000,000 shares of common stock, with gross proceeds expected to be approximately $55 million. ($55.0M proceeds)

S-3 filing: Tharimmune, Inc. may offer and sell, from time to time in one or more offerings, up to $2,000,000,000 in the aggregate of any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities.

S-3 filing: The filing relates to the potential resale of up to 176,934,358 shares of common stock by selling stockholders, as well as an ATM offering of common stock with an aggregate offering price of up to $64,910,161.

10-Q filing | 35.0M shares outstanding

S-3 filing: The selling stockholder named in this prospectus may use this prospectus to offer and resell from time to time up to 326,750 shares of our common stock.

S-3/A filing: This S-3/A filing from Tharimmune, Inc. relates to the registration for resale of up to 2,463,601 shares of common stock by certain selling shareholders.

S-3 filing: This S-3 filing describes the potential resale of common stock by selling stockholders, including shares issuable upon exercise of warrants, that were previously issued in a registered direct offering and concurrent private placement, and a private placement.

10-Q filing | 4.6M shares outstanding

8-K filing: Tharimmune, Inc. entered into a securities purchase agreement for a private placement involving the issuance and sale of common stock, pre-funded warrants, and common warrants, closing on July 31, 2025, with gross proceeds expected to be $1,225,003.

8-K filing: Tharimmune, Inc. completed a registered direct public offering of $1.74 million of securities, consisting of common stock and warrants, with the offering closing on July 25, 2025. ($1.74M proceeds)

S-3 filing: The filing relates to the registration of 4,222,948 shares of common stock for resale by selling stockholders.

8-K filing: Tharimmune, Inc. entered into a securities purchase agreement for a private placement involving the issuance and sale of common stock, pre-funded warrants, and Series A and B warrants, with the closing expected on June 20, 2025. ($2.5M proceeds)

10-Q filing | 2.6M shares outstanding

10-K filing | 2.1M shares outstanding

S-3 filing: Registration of 1,442,167 shares of common stock for resale by selling stockholders, consisting of shares issued in a private placement and shares issuable upon exercise of warrants.

8-K filing: Tharimmune, Inc. entered into a securities purchase agreement for the issuance and sale of common stock, pre-funded warrants, and common warrants in a private placement, with gross proceeds expected to be approximately $2.02 million. ($2.02M proceeds)

10-Q filing | 1.5M shares outstanding

10-Q filing | 1.1M shares outstanding

S-3 filing: This S-3 filing relates to the registration of 1,009,102 shares of common stock for resale by selling stockholders, comprised of shares issued in a private placement and shares issuable upon exercise of warrants.

8-K filing: Tharimmune, Inc. entered into a securities purchase agreement for a private placement involving the issuance and sale of common stock, pre-funded warrants, and common warrants, with gross proceeds expected to be approximately $2.08 million. ($0.35M proceeds)

8-K filing: Stock split 1-for-15 | Outstanding: 11,757,808 → 783,853

10-Q filing | 11.8M shares outstanding

10-K filing | 11.7M shares outstanding

8-K filing: Tharimmune, Inc. announced the closing of its public offering of 11,000,000 shares of common stock, with gross proceeds of approximately $11 million. ($11.0M proceeds)

8-K filing: Stock split 1-for-25 | Outstanding: 700,474 → 28,018

S-1/A filing: S-1/A filing dated 2023-11-17 for offering up to 2,105,263 shares of common stock and up to 2,105,263 pre-funded warrants to purchase up to 2,105,263 shares of common stock at an assumed public offering price of $4.75 per share.

10-Q filing | 17.3M shares outstanding

S-1 filing: This S-1 filing relates to the offering of common stock and pre-funded warrants to purchase common stock by Tharimmune, Inc.

10-Q filing | 17.5M shares outstanding

10-Q filing | 16.8M shares outstanding

8-K filing: Hillstream BioPharma, Inc. completed a public offering of 5,300,000 shares of common stock at $0.50 per share, with an option for the underwriters to purchase an additional 795,000 shares, and issued warrants to ThinkEquity to purchase shares equal to 3% of the Securities sold in the Offering at an initial exercise price of $0.625 per share. ($2.65M proceeds)

S-3 filing: Hillstream BioPharma, Inc. may offer and sell, from time to time in one or more offerings, any combination of common stock, preferred stock, debt securities, warrants to purchase common stock, preferred stock or debt securities, or any combination of the foregoing, either individually or as units comprised of one or more of the other securities, having an aggregate initial offering price not exceeding $75 million.

10-K filing | 11.3M shares outstanding

10-Q filing | 11.5M shares outstanding

10-Q filing | 11.6M shares outstanding

10-Q filing | 10.6M shares outstanding

10-K filing | 11.4M shares outstanding

S-1/A filing: This S-1/A filing details a proposed offering of common stock, with underwriters having an option to purchase additional shares. The company intends to use the net proceeds to advance their product candidates and for general corporate purposes.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock.

S-1/A filing: This S-1/A filing details a proposed offering of common stock by Hillstream BioPharma, Inc., underwritten by ThinkEquity LLC, with the intention to use the proceeds for advancing product candidates and for general corporate purposes.

S-1/A filing: S-1/A filing for common stock offering with an option for underwriters to purchase additional shares.

S-1 filing: This is an S-1 filing for an initial public offering of common stock.